Insights from the RedirecTT-1 Study: A Potential Game-Changer for R/R Myeloma with EMD

episode

Cleveland Clinic Cancer Advances not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Bringing Kashmir’s lakes back to life 25 min · 23 Sep 2026 · The Documentary Podcast

Soup 56 min · 23 Sep 2026 · Three Bean Salad

AFL Record Editor Ash Browne | Grand Final edition on sale now! (23.09.26) 2 min · 23 Sep 2026 · Whateley

NPR News: 09-22-2026 8PM EDT 4 min · 23 Sep 2026 · NPR News Now

Send Me To Sleep | Aristotle 44 min · 23 Sep 2026 · Send Me To Sleep

Finding the balance between offence & defence | The Art of Coaching with Ken Hinkley! (23.09.26) 5 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded11 Dec 2025

Publisherfeeds.buzzsprout.com

Handlerec:14526555

Show notes

Shahzad Raza, MD, Hematologist at Cleveland Clinic, joins the Cancer Advances podcast to share insights from the RedirecTT-1 study. This study, presented at the 2025 American Society of Hematology (ASH) Annual Meeting, explores combining two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed/refractory multiple myeloma with extramedullary disease. Listen as Dr. Raza discusses disease biology, outcomes, safety considerations and why this approach could be a major step forward for high-risk myeloma care.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in